Please assess the completion status of the following clinical trial:

Trial Title: Melancholic Symptoms in Bipolar Depression and Responsiveness to Lamotrigine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients must provide written and informed consent.~2. Diagnosis of Bipolar II Disorder and currently depressed for minimum of the last 8 weeks, with a HAMD-17 score of at least 18 with scores of 3 or more on Items 1 or 7.~3. For females, be of non-childbearing potential, or of childbearing potential with a negative pregnancy test at screening and agrees to one of (a) abstinence from sex two weeks prior and five days after drug continuation/discontinuation, (b) personal or partner sterilization, (c) one method of hormonal contraception, or (d) two barrier methods of contraception.~4. Acceptable results (within two times the normal limit) on laboratory screening tests (e.g., thyroid function).~Exclusion Criteria:~1. Active suicidality.~2. History of non-response to antidepressant treatment, or any previous treatment with lamotrigine.~3. History of substance dependence in the past year, or abuse within the 4 weeks prior to study entry.~4. Rapid cycling bipolar disorder.~5. Receiving additional psychoactive medication (not including lorazepam for agitation), or has started a new course of psychotherapy within the last month.~6. Received treatment for an anxiety or eating disorder within the last 12 months.~7. Investigational drug use within the last month.~8. History of epilepsy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Lamotrigine - melancholic depression (Type: EXPERIMENTAL): Participants with melancholic depression who were randomly assigned to receive lamotrigine tablets escalated to a target dose of 200mg/day.
- Placebo - melancholic depression (Type: PLACEBO_COMPARATOR): Participants with melancholic depression who were randomly assigned to receive a placebo comparator.
- Lamotrigine - nonmelancholic depression (Type: EXPERIMENTAL): Participants not meeting DSM-IV-TR diagnostic criteria for melancholic depression who were randomly assigned to receive lamotrigine tablets escalated to a target dose of 200mg/day.
- Placebo - nonmelancholic depression (Type: PLACEBO_COMPARATOR): Participants not meeting DSM-IV-TR diagnostic criteria for melancholic depression who were randomly assigned to receive a placebo comparator.

Based on this trial design, predict the completion outcome and termination type (if applicable).